SM
Schedule 13G filing
Strome Mark E disclosed a 8.5% stake in CUE
Strome Mark E reported owning 8.5% of Cue Biopharma, Inc. (CUE) (644,916 shares) in a Schedule 13G filed Oct 8, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
More CUE insider and Congress trades
From a public Schedule 13G, linked above. Not investment advice, and not a recommendation to buy or sell.